European Psychiatry - Volume 33 - March 2016

728 / 812

S724 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
EV1174
Aripiprazole once-monthly efficacy in
patients with schizophrenia. Review
M.F. Molina López ∗, M.C. Cancino Botello , A. Pe˜na Serrano ,
M.D.L.A. Canseco Navarro
1 Valencia, Spain
2 Hospital General Universitario de Valencia, Psiquiatría, Valencia,
Spain
∗ Corresponding author.
Introduction long acting injectable formulations of antipsy-
chotics are a valuable option for patients with schizophrenia,
offering continuous medication delivery and stable dosage levels.
Aripiprazole once-monthly is the first dopamine partial ago-
nist available in long acting formulation approved in Europe for
Schizophrenia with excellent results so far.
Aims to conduct a current reviewof articles related to the use and
efficacy of Aripiprazole once monthly in patients with Schizophre-
nia.
Methods systematic review of the literature in English using the
following keywords: “aripiprazole once-monthly”, “aripiprazole
long acting formulation”, “schizophrenia”. PubMed database.
Results Aripiprazole once-monthly (AOM) formulation efficacy
has been proven in many studies. The importance of maintaining
an oral overlap during 14 days is highlighted in all studies that have
been reviewed in order to reach therapeutic level; therefore, it can
be used in patients with acute decompensations. Recent studies
comparing AOM versus Paliperidone Palmitate once monthly (PP)
have shown that patients with AOM had greater clinical improve-
ment and, even though both drugs were well tolerated, when
Quality of Life Style Scale was analyzed an important improvement
in empathy, sense of purpose, emotional interaction and curiosity
in the AOM group was observed.
Conclusions long acting injectable antipsychotics increase long-
term adherence treatment and reduce risk of relapse. Because of its
unique mechanism of action, Aripiprazole once-monthly improves
positive and negative symptoms, giving the patient an opportunity
to have a better quality of life.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1175
Pharmacological wash out for
clozapine induced tics: A case report
A. Morales-Rivero ∗, M. Chavarria-Medina ,
C.L. Avina-Cervantes
1 Instituto1 Nacional de neurologia y neurocirugía, psichiatry, Mexico
City, Mexico
2 Instituto1 Nacional de neurologia y neurocirugía, Neurology,
Mexico City, Mexico
∗ Corresponding author.
Introduction Clozapine has been long used for the treatment-
resistant schizophrenia. Its effectiveness in the vast schizophrenia
symptoms is well established. However, its wide range of adverse
effects has limited its use.
Objectives/aims To present a new strategy in order to continue
with clozapine treatment despite extrapyramidal adverse effects.
Methods/case report Extrapyramidal symptoms are rarely
reported with clozapine. Although, cases of patients with
clozapine-induced tics have been described. We report the case of
a 28 year-old patient with history of refractory schizophrenia that
developed motor tics with clozapine 150mg total dose. Tics con-
sisted on eye blinking, eyebrow elevation, mouth twitching, facial
grimacing, lip licking, tongue protrusion and shoulder shrugging.
Reduction of clozapine dose to 50mg qd was indicated to decrease
the motor tics, however exacerbation of psychosis occurred.
We added amisulpride and titrated it up to 600mg qd without
response. By using the same principle of levodopa’s washout in
Parkinson disease and in order to establish a therapeutic threshold,
we conducted a one-week clozapine washout.
Results After this therapeutic manoeuvre, tics disappeared and
no relapse was observed after clozapine reinitiation along with
remission of psychotic symptoms.
Conclusions Wash out might be a new strategy for treatment
reinitiation after clozapine induced extrapyramidal side effects in
patientswith treatment-resistant schizophrenia. To our knowledge
no previous report of this strategy has been reported, however
further studies are needed to support its effectiveness.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1176
Correlation between childhood
trauma and cognitive impairment in
patients with schizophrenia
J. Mrizak∗, R. Trabelsi , A. Arous , A. Aissa , H. Ben Ammar ,
Z. El Hechmi
Razi Hospital, Psychiatry F, Mannouba, Tunisia
∗ Corresponding author.
Introduction Abusive childhood experiences are claimed to be
more prevalent in people with schizophrenia (SCZ) than in the
general population. The exposure to childhood trauma can have
adverse effects on cognitive function.
Objectives To investigatewhether there is a relationship between
childhood trauma (CT) and cognitive functioning in patients with
SCZ.
Methods Fifty-eight outpatients with stable SCZ were recruited.
The participants completed the Childhood Trauma Questionnaire
retrospectively assessing five types of childhood trauma (emo-
tional, physical and sexual abuse, and emotional and physical
neglect). They also completed a neurocognitive battery compris-
ing the following tests: the Hopkins Verbal Learning Test–Revised
(HVLT-R), the Letter Digit Substitution Test (LDST), the Stroop Test
(ST), the “Double Barrage” of Zazzo (DBZ), the Modified Card Sort-
ing Test (MCST), the Verbal Fluency (VF), the Trail Making Test-Part
A (TMT-A) and the Digit Span (DS).
Results The patients with a history of physical abuse (P = 0.03)
or emotional neglect (P = 0.07) performed worse at the delayed
recall of the HVLT-R. A history of emotional neglect was also corre-
lated to a significantlyworse performance in theTMT-A ( P < 0.0001),
while physical abuse was correlated to worse DS (P = 0.015). High
emotional abuse scores were significantly correlated to poorer effi-
ciency in DBZ ( P = 0.025).
Conclusions The results need replication, but underline the
necessity of investigating biological and psychosocial mechanisms
underlying these subjects’ cognitive impairment.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1177
Schizophrenia and sexual
desinhibition
M. Palomo Monge ∗, G.M. David , D.D. Arántzazu ,
A.L. Maria Fernanda , T.G. Maria Fernanda , M.M. Gemma ,
D.C. Sandra
1 Hospital Nuestra Se˜nora del Prado, Psychiatry, 45600 Spain
2 Hospital General de Avila, Psychiatry, Avila, Spain
3 Hospital Nuestra Se˜nora del Prado, Family Medicine, Talavera de la
Reina, Spain